Specific Photoprotection

It is even more important to use sun protection on a daily basis in the presence of skin conditions which can worsen with the sun. Our commitment to health has lead us to develop formulations designed to meet specific needs.

In addition to advanced, broad-spectrum protection, our specific formulations feature actives which specifically target and improve conditions requiring special care.

How can I choose the product best suited to my needs?

Each skin type is different and can vary over the course of our lives. A healthcare professional can analyse and assess your current situation and recommend the photoprotector that best suits your needs.

If you have acne, dark spots, actinic keratosis or sensitive or reactive skin, we want to to provide you with the best possible skincare and most suitable photoprotection. Visit your dermatologist and consult your pharmacist to find the HELIOCARE photoprotector designed for you.

Acne-prone skin

HELIOCARE

360º

Gel Oil-Free SPF 50

Advanced photoprotection with seboregulating and mattifying active ingredients.

Actinic keratosis

HELIOCARE

360º

MD AK Fluid

Prevention and adjuvant protective treatment of actinic keratosis and other forms of non-melanoma skin cancer.

Sensitive and intolerant skin

HELIOCARE

360º

Mineral Tolerance Fluid SPF 50

Advanced photoprotection with 100% mineral filters, light texture with no lightening effect.

Other Photoprotection Needs

Lo último del Área de Comunicación

News 30 Oct 2020

Cantabria Labs acquires the ELANCYL body care brand from Pierre Fabre

Spanish pharmaceutical company Cantabria Labs has bought ELANCYL, the expert body care brand, after reaching an acquisition agreement with the...
rafa-nadal-cantabrialabs
News 12 May 2020

Rafa Nadal with HELIOCARE: “Give your all for what matters never to the sun”

• The Spanish tennis ace is the face of the “Give Your All for What Matters never to the Sun”...
News 7 May 2020

Cantabria Labs collaborates in the Covid-19 research project of Alcalá University

The study led by the University Professor Melchor Álvarez de Mon, seeks to identify precisely which medicines and what treatments will...